Author:
Kumar Saurabh,Devi Chandra,Sarkar Subhabrata,Kumar Garg Vivek,Choudhary Priyanka,Chopra Madhu,Sharma Vinit,Prakash Ravi
Abstract
Novel Coronavirus (nCoV-2019) is a highly infectious viral outbreak that has so far infected more than 110 million people worldwide. Fast viral transmission and high infection rates have severely affected the entire population, especially the old aged and comorbid individuals leaving significantly less time to find some effective treatment strategy. In these challenging times, convalescent plasma (CP) therapy came as a ray of hope to save humankind. It is a form of passive immunization that has been used to treat various infectious diseases since 1890, including the 1918 Spanish flu, 2002/03 SARS-CoV, 2009 H1N1, 2012 MERS-CoV, and 2014 Ebola outbreak. The transfusion includes administration of CP containing a high value of neutralizing antibodies against the virus in hospitalized patients. This chapter summarizes the potential outcome of CP therapy in the treatment of nCoV-2019 patients.
Reference69 articles.
1. Anudeep T, Jeyaraman M, Shetty DU, Raj H, Ajay S, Somasundaram R, et al. Convalescent Plasma as a plausible therapeutic option in nCOVID-19–A Review. J Clin Trials. 2020;10:2167-0870.20. DOI: 10.35248/2167-0870.20.10.409
2. Kumar S, Sharma V, Priya K. Battle against COVID-19: Efficacy of sConvalescent Plasma as an emergency therapy. Am J Emerg Med. 2020. DOI: 10.1016/j.ajem.2020.05.101
3. Brown BL, McCullough J. Treatment for emerging viruses: Convalescent plasma and COVID-19. Transfus Apher Sci. 2020. DOI: 10.1016/j.transci.2020.102790
4. Diorio C, Teachey DT, Bassiri H. Convalescent plasma for COVID-19: an old therapy for a novel pathogen. The Hematologist. 2020;17:. DOI: 10.1182/hem.V17.4.10407
5. Behring K, Kitasato S. On the development of immunity to diphtheria and tetanus in animals. Dtsch Med Wochenschr. 1965;90:2183.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献